We conclude that IL-35 plays a critical role in the pathogenesis of psoriasis by regulating iNOS-expressing MDSCs, highlighting IL-35 as a novel therapeutic strategy for psoriasis or other cutaneous inflammatory diseases. The gene discussed is NOS2; the disease is psoriasis.